Please assess the completion status of the following clinical trial:

Trial Title: Olmesartan Medoxomil in Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetes mellitus type 2, defined as fasting blood glucose of greater than or equal to 126 mg/dL;~* Presence of at least one of the following cardiovascular risk factors:~  1. total cholesterol greater than 200 mg/dL or statin treatment,~ 2. High density lipoprotein (HDL) less than 40 mg/dL,~ 3. triglycerides greater than 150 mg/dL and less than 400 mg/dL,~ 4. blood pressure greater than or equal to 130/80 mmHg,~ 5. Body mass index (BMI) greater than 28 kg/m2,~ 6. waist circumference greater than 102 cm for men and greater than 88 cm for women,~ 7. smoking of more than 5 cigarettes a day;~* Normoalbuminuria at screening~Exclusion Criteria:~* Severe uncontrolled hyperlipidemia;~* Documented renal and/or renal-vascular disease;~* Myocardial infarction, stroke or myocardial revascularization within the last 6 months;~* History of alcohol and/or drug abuse;~* Allergic reaction, lack of response or contraindication to angiotensin receptor blockers (ARBs);~* Current treatment with an ARB or angiotensin converting enzyme (ACE) inhibitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): olmesartan medoxomil
- 2 (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).